You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites.
Cancel Ok

Temanogrel


Temanogrel

A drug candidate for the prevention and treatment of coronary microvascular obstruction. Temanogrel is an investigational, peripherally acting, and selective 5-HT2A receptor inverse agonist designed to inhibit serotonin (5-HT)-mediated amplification of platelet aggregation and vasoconstriction. Temanogrel will be entering Phase 2 for coronary microvascular obstruction, or cMVO, in H1 2021.
Clinical Trial
CORONARY MICROVASCULAR OBSTRUCTION
Phase 2
Temanogrel is an investigational drug and is not currently approved for use by any health authority.
Retained Rights: Worldwide.